Capstone Investment Advisors’s Novavax NVAX Stock Holding History

Capstone Investment Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,500	Closed	-$50K	–	1422
2019 Q1	$50K	Buy	+4,500	New	+$142K	﹤0.01%	1226

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capstone Investment Advisors's NVAX Position: Q4 2024 in Review

Capstone Investment Advisors sold out of Novavax (NVAX) in Q4 2024, closing a stake of 3,360 shares — an estimated $32.4K sold.

Capstone Investment Advisors first reported a position in NVAX in Q3 2016 and held it in 7 quarters. The position peaked at $393K in Q3 2016. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

Capstone Investment Advisors reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
Capstone Investment Advisors sold 3,360 Novavax shares in Q4 2024, an estimated $32.4K.
Capstone Investment Advisors first reported a position in Novavax in Q3 2016 and held it in 7 quarters.
Capstone Investment Advisors's Novavax position peaked at $393K in Q3 2016.
235 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on Capstone Investment Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.